{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:32:03Z","timestamp":1794634323299,"version":"4.9.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05571-y","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T10:47:56Z","timestamp":1710931676000},"page":"2431-2434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7650-2582","authenticated-orcid":false,"given":"Nicola","family":"Farina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-2078","authenticated-orcid":false,"given":"Alessandro","family":"Tomelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4416-933X","authenticated-orcid":false,"given":"Nicola","family":"Boffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Cariddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9685-4582","authenticated-orcid":false,"given":"Stefania","family":"Calvisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9292-3851","authenticated-orcid":false,"given":"Elena","family":"Baldissera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-3161","authenticated-orcid":false,"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-315X","authenticated-orcid":false,"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"issue":"7","key":"5571_CR1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/ard-2023-223885","volume":"82","author":"AR Bass","year":"2023","unstructured":"Bass AR, Abdel-Wahab N, Reid PD, Sparks JA, Calabrese C, Jannat-Khah DP et al (2023) Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis 82(7):920\u2013926","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5571_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"issue":"7","key":"5571_CR3","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1084\/jem.20090207","volume":"206","author":"L Wang","year":"2009","unstructured":"Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6\u2013Stat3 signaling pathway. J Exp Med 206(7):1457","journal-title":"J Exp Med"},{"issue":"1","key":"5571_CR4","doi-asserted-by":"publisher","first-page":"e20190297","DOI":"10.1084\/jem.20190297","volume":"217","author":"J Zhao","year":"2020","unstructured":"Zhao J, Chen X, Herjan T, Li X (2020) Cytokines focus: the role of interleukin-17 in tumor development and progression. J Exp Med 217(1):e20190297","journal-title":"J Exp Med"},{"issue":"3","key":"5571_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/hum.2018.104","volume":"30","author":"YS Chen","year":"2019","unstructured":"Chen YS, Huang TH, Liu CL, Chen HS, Lee MH, Chen HW et al (2019) Locally targeting the IL-17\/IL-17RA axis reduced tumor growth in a murine B16F10 melanoma model. Hum Gene Ther 30(3):273\u2013285","journal-title":"Hum Gene Ther"},{"issue":"5","key":"5571_CR6","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/bjd.20136","volume":"185","author":"M Lebwohl","year":"2021","unstructured":"Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W et al (2021) The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol 185(5):935\u2013944","journal-title":"Br J Dermatol"},{"issue":"1","key":"5571_CR7","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1097\/RHU.0000000000001590","volume":"28","author":"PH Li","year":"2022","unstructured":"Li PH, Wai Chan SC, Lau CS, Yan Seto MT, Chung HY (2022) Conventional and biologic disease-modifying antirheumatic drugs are not associated with increase in or progression of cervical neoplasia among patients with spondyloarthritis. J Clin Rheumatol 28(1):E63\u2013E68","journal-title":"J Clin Rheumatol"},{"issue":"11","key":"5571_CR8","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s13555-022-00797-9","volume":"12","author":"C Pellegrini","year":"2022","unstructured":"Pellegrini C, Esposito M, Rossi E, Gisondi P, Piaserico S, Dapavo P et al (2022) Secukinumab in patients with psoriasis and a personal history of malignancy: a multicenter real-life observational study. Dermatol Ther (Heidelb). 12(11):2613","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"5571_CR9","doi-asserted-by":"publisher","first-page":"E318","DOI":"10.1097\/RHU.0000000000001699","volume":"28","author":"E Tekgoz","year":"2022","unstructured":"Tekgoz E, Colak S, Yardimci KG, Kucuksahin O, Cinar M, Yilmaz S et al (2022) Physicians\u2019 biological drug preference in patients with rheumatoid arthritis and spondyloarthritis with a history of malignancy: perspectives from the treasure database. J Clin Rheumatol 28(2):E318\u2013E323","journal-title":"J Clin Rheumatol"},{"key":"5571_CR10","doi-asserted-by":"crossref","unstructured":"Monsour EP, Pothen J, Balaraman R. A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report. Cureus [Internet]. 2019 Oct 2 [cited 2023 Dec 2];11(10). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31754559\/","DOI":"10.7759\/cureus.5824"},{"issue":"8","key":"5571_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2217\/imt-2021-0274","volume":"14","author":"VT Ma","year":"2022","unstructured":"Ma VT, Lao CD, Fecher LA, Schiopu E (2022) Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. Immunotherapy 14(8):593\u2013598","journal-title":"Immunotherapy"},{"issue":"6","key":"5571_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Van Der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777\u2013783","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5571_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, Van Der Heijde D, Landew\u00e9 R, Akkoc N, Brandt J, Chou CT et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25\u201331","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"5571_CR14","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMc1703047","volume":"376","author":"K Esfahani","year":"2017","unstructured":"Esfahani K, Miller WH (2017) Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 376(20):1989\u20131991","journal-title":"N Engl J Med"},{"key":"5571_CR15","doi-asserted-by":"publisher","DOI":"10.5070\/D327654071","author":"SP Saura","year":"2021","unstructured":"Saura SP, Casimiro LM, V\u00e1zquez AG, Benavent MP, Guill\u00e9n-Climent S, Villaescusa EM (2021) Successful outcome of psoriasis in a laryngeal cancer patient treated with ixekizumab, a possible beneficial treatment for both pathologies. Dermatol Online J. https:\/\/doi.org\/10.5070\/D327654071","journal-title":"Dermatol Online J"},{"issue":"4","key":"5571_CR16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1684\/ejd.2021.4087","volume":"31","author":"A Vinaixa-Aranzazu","year":"2021","unstructured":"Vinaixa-Aranzazu A, Morillas-Lahuerta V, Blanco-De-Tord M, Carrascosa-Carrillo JM (2021) Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient. Eur J Dermatol 31(4):564\u2013565","journal-title":"Eur J Dermatol"},{"issue":"1","key":"5571_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/15476910801897953","volume":"5","author":"C Dong","year":"2008","unstructured":"Dong C (2008) IL-23\/IL-17 biology and therapeutic considerations. J Immunotoxicol 5(1):43\u201346","journal-title":"J Immunotoxicol"},{"key":"5571_CR18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190297","author":"J Zhao","year":"2020","unstructured":"Zhao J, Chen X, Herjan T, Li X (2020) The role of interleukin-17 in tumor development and progression. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20190297","journal-title":"J Exp Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05571-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05571-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05571-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:25:15Z","timestamp":1727299515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05571-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["5571"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05571-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"28 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AT, NB, EB, MMC, LD received consultation honoraria from Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}